- $36.55m
- $29.39m
- $0.04m
Annual income statement for RenovoRx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0.043 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 0.043 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3.2 | 5.61 | 9.95 | 11.4 | 11 |
| Operating Profit | -3.2 | -5.61 | -9.95 | -11.4 | -11 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.8 | -6.32 | -9.89 | -10.2 | -8.81 |
| Net Income After Taxes | -3.8 | -6.32 | -9.89 | -10.2 | -8.81 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.8 | -6.32 | -9.89 | -10.2 | -8.81 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.8 | -6.32 | -9.89 | -10.2 | -8.81 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.453 | -1.22 | -1.09 | -0.994 | -0.396 |
| Dividends per Share |